Taken together, these results indicated that BsAb5003 has the potential to deplete malignant cells in ND-/ RR-MM patients, including SoC-resistant, and post-BCMA patients, and those with high-risk cytogenetics. Here, UBXN11 is linked to Miyoshi myopathy.